Overview

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

Status:
Unknown status
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety after administration of HCP1105 in hyperlipidemic patients with high risk for CHD.
Phase:
Phase 3
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited